ストックスクリーナーアプリを入手
3.00
2.04%
0.06
アフターアワーズ：
3.01
0.010
+0.33%
Altimmune Inc (ALT) 最新ニュース
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Altimmune Stock Price Forecast. Should You Buy ALT? - StockInvest.us
9 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Altimmune (ALT) Q2 2026 Earnings Call: PERFORMA Starts, Cash Reaches $519M - TradingKey
ALT|Altimmune Inc|Price:2.940|Chg%:+0.060 - TradingKey
Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares - GuruFocus
Altimmune CEO Jerome Benedict Durso Buys 15,000 Shares at $2.95 Each - Kalkine Media
Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each - Stock Titan
Altimmune: Pemvidutide Performs, But A Long Wait Ahead (NASDAQ:ALT) - Seeking Alpha
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - The Globe and Mail
Barclays Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript - GuruFocus
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Altimmune (NASDAQ:ALT): What Does the Latest Update Mean for Trial Execution? - kalkinemedia.com
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT - marketbeat.com
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... - Yahoo Finance Australia
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancin - GuruFocus
Altimmune Reports Q2 2026 Financial Results and SEC Filing Highlighting Increased Assets and Equity Raise - kalkinemedia.com
Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary - TradingView
Altimmune (ALT) grows cash reserves above $518M while advancing Phase 3 MASH trial - Stock Titan
Altimmune (ALT) Advances Clinical Trials Amidst High Price-to-Sa - GuruFocus
Altimmune Releases Q2 2026 Financial Results - AlphaStreet
William Blair Maintains Altimmune(ALT.US) With Hold Rating - Moomoo
Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - marketbeat.com
Altimmune Q2 EPS $(0.12) beats $(0.15) estimate - scanx.trade
Earnings call transcript: Altimmune tops Q2 2026 EPS view as shares rise - Investing.com Australia
Altimmune Q2 Earnings Call Highlights - MarketBeat
Altimmune (ALT) Q2 Earnings Beat Expectations but Remain Unprofi - GuruFocus
Q2 2026 Altimmune Inc Earnings Call Transcript - GuruFocus
Form 8K Altimmune Inc For: 12 August By Investing.com - Investing.com South Africa
Altimmune posts smaller-than-expected Q2 net loss per share - TradingView
Altimmune posts $22.8M Q2 net loss, $519M cash; advances pemvidutide Phase 3 and Phase 2 programs - TradingView
Altimmune Announces Second Quarter 2026 Financial Results and Business Update - manilatimes.net
Altimmune Reports $22.8 Million Q2 Loss and Advances Pemvidutide Trials - Quiver Quantitative
Altimmune (NASDAQ:ALT): What Could Today’s clinical evidence and program focus Update Reveal? - Kalkine Media
Altimmune Inc (ALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Altimmune (ALT) Q2 Earnings Preview: Unpacking Valuation and Guru Ownership Signals - GuruFocus
Altimmune (ALT) Earnings Date and Reports 2026 $ALT - MarketBeat
Altimmune Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Weekly Recap: Altimmune (ALT) PERFORMA Phase 3 launch and Aug 12 results - TradingView
Altimmune Inc (ALT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Altimmune, Inc. (ALT) options chain – Yahoo Finance - sg.finance.yahoo.com
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Altimmune to discuss its liver-treatment candidate Aug. 12 - Stock Titan
ALT Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
Altimmune (ALT) Projected to Release Quarterly Earnings on Tuesday - marketbeat.com
Altimmune (ALT) CSO acquires 875 ESPP shares at $2.414 - Stock Titan
Altimmune (ALT) CFO acquires 1,753 shares via employee stock purchase plan - Stock Titan
Altimmune (ALT) Begins Enrollment in Phase 3 Trial Amid High Pri - GuruFocus
Altimmune begins phase 3 trial of pemvidutide for MASH - Investing.com
Altimmune begins phase 3 trial of pemvidutide for MASH By Investing.com - Investing.com Nigeria
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - The Manila Times
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):